Poly Medicure, India's largest medical device company announced its acquisition of 90% of the PendraCare Group, including PendraCare Holdings and Wellinq Medical, from Wellinq Holdings B.V. The deal has an enterprise value of €18.3 million...
In an exclusive interview with Thiruamuthan, Correspondent at India Pharma Outlook, Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science, discusses how a dedicated formulation and technology centre addresses complex challenges i
The last ten years have seen unprecedented international momentum in GLP-1 obesity and diabetes treatment with injectable preparations changing the standard of care. The introduction of oral GLP-1 drugs is now a significant breakthrough, and it...
Granules India Limited, in collaboration with the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, has officially opened the Dr. Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical
Servier, an independent global pharmaceutical organization governed by a foundation, along with IDEAYA Biosciences, Inc., a prominent precision medicine oncology firm, have declared an exclusive licensing agreement aimed at making darovasertib
Caplin Point Laboratories Ltd revealed today that its subsidiary Caplin Steriles Ltd has received final approval from the United States Food and Drug Administration (USFDA) for its generic Milrinone Lactate in 5% Dextrose Injection. Milrinone is...
As part of the uniform code for marketing practices, manufacturers of medical devices are allowed to give doctors free evaluation samples so they can get firsthand experience using the product
Future presentations at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress have been announced by
A UK-wide Commercial Research Delivery Centre (CRDC) Network will be established thanks to a £6.5 million investment from the National Institute for Health and Care Research (NIHR), which was made possible by public-private cooperation
Glenmark Pharmaceuticals has announced its plans to launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, in the United States this September. The product was determined to be bioequivalent and therapeutically equivalent...
.jpg)
, CDSCO.jpg)